UniProt ID | SAP_HUMAN | |
---|---|---|
UniProt AC | P07602 | |
Protein Name | Prosaposin | |
Gene Name | PSAP | |
Organism | Homo sapiens (Human). | |
Sequence Length | 524 | |
Subcellular Localization |
Lysosome . Prosaposin: Secreted . Secreted as a fully glycosylated 70 kDa protein composed of complex glycans. |
|
Protein Description | Saposin-A and saposin-C stimulate the hydrolysis of glucosylceramide by beta-glucosylceramidase (EC 3.2.1.45) and galactosylceramide by beta-galactosylceramidase (EC 3.2.1.46). Saposin-C apparently acts by combining with the enzyme and acidic lipid to form an activated complex, rather than by solubilizing the substrate.; Saposin-B stimulates the hydrolysis of galacto-cerebroside sulfate by arylsulfatase A (EC 3.1.6.8), GM1 gangliosides by beta-galactosidase (EC 3.2.1.23) and globotriaosylceramide by alpha-galactosidase A (EC 3.2.1.22). Saposin-B forms a solubilizing complex with the substrates of the sphingolipid hydrolases.; Saposin-D is a specific sphingomyelin phosphodiesterase activator (EC 3.1.4.12).; Prosaposin: Behaves as a myelinotrophic and neurotrophic factor, these effects are mediated by its G-protein-coupled receptors, GPR37 and GPR37L1, undergoing ligand-mediated internalization followed by ERK phosphorylation signaling.; Saposins are specific low-molecular mass non-enzymic proteins, they participate in the lysosomal degradation of sphingolipids, which takes place by the sequential action of specific hydrolases.. | |
Protein Sequence | MYALFLLASLLGAALAGPVLGLKECTRGSAVWCQNVKTASDCGAVKHCLQTVWNKPTVKSLPCDICKDVVTAAGDMLKDNATEEEILVYLEKTCDWLPKPNMSASCKEIVDSYLPVILDIIKGEMSRPGEVCSALNLCESLQKHLAELNHQKQLESNKIPELDMTEVVAPFMANIPLLLYPQDGPRSKPQPKDNGDVCQDCIQMVTDIQTAVRTNSTFVQALVEHVKEECDRLGPGMADICKNYISQYSEIAIQMMMHMQPKEICALVGFCDEVKEMPMQTLVPAKVASKNVIPALELVEPIKKHEVPAKSDVYCEVCEFLVKEVTKLIDNNKTEKEILDAFDKMCSKLPKSLSEECQEVVDTYGSSILSILLEEVSPELVCSMLHLCSGTRLPALTVHVTQPKDGGFCEVCKKLVGYLDRNLEKNSTKQEILAALEKGCSFLPDPYQKQCDQFVAEYEPVLIEILVEVMDPSFVCLKIGACPSAHKPLLGTEKCIWGPSYWCQNTETAAQCNAVEHCKRHVWN | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
|
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
9 | Phosphorylation | YALFLLASLLGAALA HHHHHHHHHHHHHHH | 24.89 | - | |
27 | Methylation | LGLKECTRGSAVWCQ CCCCCCCCCCEEEEC | 49.04 | 115489243 | |
55 | Ubiquitination | CLQTVWNKPTVKSLP HHHHHHCCCCCCCCC | 26.76 | - | |
71 | Phosphorylation | DICKDVVTAAGDMLK CHHHHHHHHHHHHHH | 15.61 | 26437602 | |
80 | N-linked_Glycosylation | AGDMLKDNATEEEIL HHHHHHCCCCHHHHH | 47.37 | 2842863 | |
80 | N-linked_Glycosylation | AGDMLKDNATEEEIL HHHHHHCCCCHHHHH | 47.37 | 2842863 | |
82 | O-linked_Glycosylation | DMLKDNATEEEILVY HHHHCCCCHHHHHHH | 50.62 | 30059200 | |
82 | Phosphorylation | DMLKDNATEEEILVY HHHHCCCCHHHHHHH | 50.62 | - | |
89 | Phosphorylation | TEEEILVYLEKTCDW CHHHHHHHHHHHCCC | 13.00 | - | |
93 | O-linked_Glycosylation | ILVYLEKTCDWLPKP HHHHHHHHCCCCCCC | 13.30 | 30059200 | |
101 | N-linked_Glycosylation | CDWLPKPNMSASCKE CCCCCCCCCCHHHHH | 43.07 | 2842863 | |
103 | O-linked_Glycosylation | WLPKPNMSASCKEIV CCCCCCCCHHHHHHH | 24.54 | 30059200 | |
112 | Phosphorylation | SCKEIVDSYLPVILD HHHHHHHHHHHHHHH | 20.06 | - | |
113 | Phosphorylation | CKEIVDSYLPVILDI HHHHHHHHHHHHHHH | 15.57 | - | |
143 | Ubiquitination | NLCESLQKHLAELNH HHHHHHHHHHHHHHH | 45.97 | - | |
152 | Ubiquitination | LAELNHQKQLESNKI HHHHHHHHHHHHCCC | 49.66 | - | |
152 | 2-Hydroxyisobutyrylation | LAELNHQKQLESNKI HHHHHHHHHHHHCCC | 49.66 | - | |
165 | Phosphorylation | KIPELDMTEVVAPFM CCCCCCCHHHHHHHH | 25.87 | - | |
165 | O-linked_Glycosylation | KIPELDMTEVVAPFM CCCCCCCHHHHHHHH | 25.87 | OGP | |
180 | Phosphorylation | ANIPLLLYPQDGPRS HCCCEEECCCCCCCC | 9.98 | - | |
187 | Phosphorylation | YPQDGPRSKPQPKDN CCCCCCCCCCCCCCC | 52.39 | - | |
214 | O-linked_Glycosylation | DIQTAVRTNSTFVQA HHHHHHHCCCHHHHH | 27.24 | OGP | |
215 | N-linked_Glycosylation | IQTAVRTNSTFVQAL HHHHHHCCCHHHHHH | 28.61 | 19167329 | |
216 | O-linked_Glycosylation | QTAVRTNSTFVQALV HHHHHCCCHHHHHHH | 23.70 | 30059200 | |
237 | Sulfoxidation | CDRLGPGMADICKNY HHHHCCCHHHHHHHH | 3.22 | 28465586 | |
281 | Phosphorylation | VKEMPMQTLVPAKVA HHHCCCHHCCCHHHC | 24.38 | 20068231 | |
290 | Ubiquitination | VPAKVASKNVIPALE CCHHHCCCCCCCHHH | 45.56 | - | |
303 | 2-Hydroxyisobutyrylation | LELVEPIKKHEVPAK HHHHCCHHHCCCCCC | 59.81 | - | |
303 (in isoform 1) | Ubiquitination | - | 59.81 | 21906983 | |
303 | Ubiquitination | LELVEPIKKHEVPAK HHHHCCHHHCCCCCC | 59.81 | 21906983 | |
305 (in isoform 2) | Ubiquitination | - | 35.96 | 21906983 | |
306 (in isoform 3) | Ubiquitination | - | 60.10 | 21906983 | |
323 | Ubiquitination | EVCEFLVKEVTKLID HHHHHHHHHHHHHHH | 48.92 | - | |
332 | N-linked_Glycosylation | VTKLIDNNKTEKEIL HHHHHHCCCCHHHHH | 49.21 | 19167329 | |
334 | O-linked_Glycosylation | KLIDNNKTEKEILDA HHHHCCCCHHHHHHH | 55.18 | 30059200 | |
336 | Ubiquitination | IDNNKTEKEILDAFD HHCCCCHHHHHHHHH | 56.11 | - | |
344 | Ubiquitination | EILDAFDKMCSKLPK HHHHHHHHHHHCCCH | 35.04 | - | |
344 | Acetylation | EILDAFDKMCSKLPK HHHHHHHHHHHCCCH | 35.04 | 27452117 | |
391 | O-linked_Glycosylation | MLHLCSGTRLPALTV HHHHCCCCCCCEEEE | 16.85 | OGP | |
397 | O-linked_Glycosylation | GTRLPALTVHVTQPK CCCCCEEEEEEECCC | 15.63 | 55824899 | |
401 | O-linked_Glycosylation | PALTVHVTQPKDGGF CEEEEEEECCCCCCH | 25.03 | 55824903 | |
413 | Acetylation | GGFCEVCKKLVGYLD CCHHHHHHHHHHHHH | 55.08 | 25953088 | |
414 | Ubiquitination | GFCEVCKKLVGYLDR CHHHHHHHHHHHHHH | 43.19 | - | |
414 | Malonylation | GFCEVCKKLVGYLDR CHHHHHHHHHHHHHH | 43.19 | 26320211 | |
418 | Phosphorylation | VCKKLVGYLDRNLEK HHHHHHHHHHHHCCC | 9.65 | - | |
421 | Methylation | KLVGYLDRNLEKNST HHHHHHHHHCCCCCC | 47.22 | 115489251 | |
426 | N-linked_Glycosylation | LDRNLEKNSTKQEIL HHHHCCCCCCHHHHH | 45.60 | 19167329 | |
427 | O-linked_Glycosylation | DRNLEKNSTKQEILA HHHCCCCCCHHHHHH | 48.31 | 30059200 | |
429 | Ubiquitination | NLEKNSTKQEILAAL HCCCCCCHHHHHHHH | 45.84 | - | |
438 | 2-Hydroxyisobutyrylation | EILAALEKGCSFLPD HHHHHHHHHHCCCCC | 67.10 | - | |
449 | Ubiquitination | FLPDPYQKQCDQFVA CCCCHHHHHHHHHHH | 47.23 | - | |
473 | Phosphorylation | LVEVMDPSFVCLKIG HHHHCCCCCEEEEEC | 26.50 | 27362937 | |
487 | Ubiquitination | GACPSAHKPLLGTEK CCCCCCCCCCCCCCC | 36.76 | - |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of SAP_HUMAN !! |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of SAP_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of SAP_HUMAN !! |
Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
---|---|---|---|---|
CSN6_HUMAN | COPS6 | physical | 16169070 | |
CATD_HUMAN | CTSD | physical | 12083803 | |
SAP_HUMAN | PSAP | physical | 12518053 | |
ZBED1_HUMAN | ZBED1 | physical | 16713569 | |
TCRG1_HUMAN | TCERG1 | physical | 22939629 | |
SMRC2_HUMAN | SMARCC2 | physical | 22939629 | |
UPAR_HUMAN | PLAUR | physical | 22939629 | |
SNP23_HUMAN | SNAP23 | physical | 22939629 | |
SURF4_HUMAN | SURF4 | physical | 22939629 | |
U2AF1_HUMAN | U2AF1 | physical | 22939629 | |
SUMO2_HUMAN | SUMO2 | physical | 22939629 | |
SYUA_HUMAN | SNCA | physical | 22939629 | |
SRSF5_HUMAN | SRSF5 | physical | 22939629 | |
SSRA_HUMAN | SSR1 | physical | 22939629 | |
TR150_HUMAN | THRAP3 | physical | 22939629 |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
611721 | Combined saposin deficiency (CSAPD) | |||||
249900 | Leukodystrophy metachromatic due to saposin-B deficiency (MLD-SAPB) | |||||
610539 | Gaucher disease, atypical, due to saposin C deficiency (AGD) | |||||
611722 | Krabbe disease, atypical, due to saposin A deficiency (AKRD) | |||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
N-linked Glycosylation | |
Reference | PubMed |
"Glycoproteomics analysis of human liver tissue by combination ofmultiple enzyme digestion and hydrazide chemistry."; Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.; J. Proteome Res. 8:651-661(2009). Cited for: GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-80; ASN-101; ASN-332 ANDASN-426, AND MASS SPECTROMETRY. | |
"Coding of two sphingolipid activator proteins (SAP-1 and SAP-2) bysame genetic locus."; O'Brien J.S., Kretz K.A., Dewji N., Wenger D.A., Esch F.,Fluharty A.L.; Science 241:1098-1101(1988). Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 14-524. |